Chengdu MedGenCell Co., Ltd

(1) Primary objective: To evaluate the safety and tolerability of autologous infusion of PD-1 gene-edited T cell injection (PD-1-KO-T cell injection) in advanced non-small cell lung cancer; (2) Secondary objective: To preliminarily evaluate the efficacy of autologous infusion of PD-1 gene-edited T cell injection (PD-1-KO-T cell injection); (3) Exploratory objective: Changes in immunological indicators and biomarkers; In vivo tracking of therapeutic cells, and exploration of the mechanism by which therapeutic cells exert their effects in the body.